Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma DOI Creative Commons

Young-min Jee,

Jeong‐Yoon Lee, Tom Ryu

и другие.

Biomedicines, Год журнала: 2025, Номер 13(5), С. 1260 - 1260

Опубликована: Май 21, 2025

Background/Objectives: Metabolic-dysfunction-associated steatotic liver disease (MASLD) progresses from hepatic steatosis to hepatocellular carcinoma (HCC) as a result of systemic immunometabolic dysfunction. This review summarizes the key roles innate and adaptive immune mechanisms driving injury, fibrogenesis, carcinogenesis in MASLD. Methods: A comprehensive literature was performed using PubMed identify relevant published studies. Eligible articles included original research clinical studies addressing immunological metabolic MASLD, well emerging therapeutic strategies. Results: We highlight cytokine networks, gut–liver axis, cell reprogramming. Emerging strategies, including inhibitors, anti-fibrotic agents, modulators, nutraceuticals, offer several indications for attenuating MASLD progression reducing prevalence extrahepatic manifestations. Conclusions: Given heterogeneity personalized combination-based approaches targeting both inflammation stress are essential effective management prevention complications.

Язык: Английский

Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Impacts Long‐Term Outcomes After Curative‐Intent Surgery for Hepatocellular Carcinoma DOI Creative Commons
Deniz Uluk,

Justus Pein,

Stefanie Herda

и другие.

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Фев. 18, 2025

ABSTRACT Background Curative surgery for hepatocellular carcinoma (HCC) includes liver resection (LR) and orthotopic transplantation (OLT). Due to the obesity epidemic, metabolic dysfunction‐associated steatotic disease (MASLD) is a frequent HCC aetiology that often coincides with increased alcohol consumption, termed MetALD, or even alcohol‐associated (ALD). Methods Patients undergoing LR OLT at Charité—Universitätsmedizin Berlin (2010–2020) were included in this retrospective cohort study investigating aetiology, time recurrence (TTR), overall survival (OS) CT‐based body composition. Results Out of 579 patients HCC, 417 underwent 162 OLT. Tumour aetiologies viral n = 191 (33.0%), MASLD 158 (27.3%), MetALD 51 (8.8%), ALD 68 (11.7%) other/cryptogenic 111 (19.2%). had more intramuscular ( p < 0.001, 0.015) visceral fat (both 0.001) than non‐metabolic dysfunction aetiologies. MASLD‐HCC comparable TTR (median 26 months, [95% CI: 23–31] vs. 30 months 4–57], 0.425) but shorter OS other (63 42–84] 80 60–100], hazard ratio: 1.53 1.050–2.229], 0.026) after LR. Multivariate analysis confirmed portal vein thrombosis MELD score ≥ 10 as independent prognostic factors (adjusted 0.021, 0.003), excluding in‐hospital mortality 0.016, 0.002, 0.002). Causes death similar non‐MASLD aetiology. Conclusions meeting new criteria have significantly OS. This provides empirical evidence novel MASLD/MetALD classification large European curative‐intent therapy.

Язык: Английский

Процитировано

2

Spatial‒temporal heterogeneities of liver cancer and the discovery of the invasive zone DOI Creative Commons
Jiayan Yan, Zhifeng Jiang, Shiyu Zhang

и другие.

Clinical and Translational Medicine, Год журнала: 2025, Номер 15(2)

Опубликована: Фев. 1, 2025

Solid tumours are intricate and highly heterogeneous ecosystems, which grow in invade normal organs. Their progression is mediated by cancer cells' interaction with different cell types, such as immune cells, stromal cells endothelial the extracellular matrix. Owing to its high incidence, aggressive growth resistance local systemic treatments, liver has particularly mortality rates worldwide. In recent decades, spatial heterogeneity garnered significant attention an unfavourable biological characteristic of tumour microenvironment, prompting extensive research into role development. Advances omics have facilitated detailed analysis states cell‒cell interactions, allowing a thorough understanding temporal heterogeneities microenvironment informing development novel therapeutic approaches. This review illustrates latest discovery invasive zone, systematically introduced specific macroscopic heterogeneities, pathological cancer.

Язык: Английский

Процитировано

1

Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma DOI

Jia-yan Ni,

Hongliang Sun,

Ge-Fan Guo

и другие.

International Immunopharmacology, Год журнала: 2024, Номер 140, С. 112872 - 112872

Опубликована: Авг. 8, 2024

Язык: Английский

Процитировано

3

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply DOI
Isabella Lurje, Deniz Uluk, Frank Tacke

и другие.

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Апрель 4, 2025

Язык: Английский

Процитировано

0

Tumor-Associated Macrophages: Polarization, Immunoregulation, and Immunotherapy DOI Creative Commons
Abdullah F. U. H. Saeed

Cells, Год журнала: 2025, Номер 14(10), С. 741 - 741

Опубликована: Май 19, 2025

Tumor-associated macrophages’ (TAMs) origin, polarization, and dynamic interaction in the tumor microenvironment (TME) influence cancer development. They are essential for homeostasis, monitoring, immune protection. Cells from bone marrow or embryonic progenitors dynamically polarize into pro- anti-tumor M2 M1 phenotypes based on cytokines metabolic signals. Recent advances TAM heterogeneity, characterization, immunological responses, therapy described here. The manuscript details functions their role resistance to PD-1/PD-L1 blockade. Similarly, TAM-targeted approaches, such as CSF-1R inhibition PI3Kγ-driven reprogramming, discussed address immunity suppression. Furthermore, innovative biomarkers combination may enhance TAM-centric therapies. It also stresses relevance of this distinct cell human health disease, which could impact future research

Язык: Английский

Процитировано

0

Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma DOI Creative Commons

Young-min Jee,

Jeong‐Yoon Lee, Tom Ryu

и другие.

Biomedicines, Год журнала: 2025, Номер 13(5), С. 1260 - 1260

Опубликована: Май 21, 2025

Background/Objectives: Metabolic-dysfunction-associated steatotic liver disease (MASLD) progresses from hepatic steatosis to hepatocellular carcinoma (HCC) as a result of systemic immunometabolic dysfunction. This review summarizes the key roles innate and adaptive immune mechanisms driving injury, fibrogenesis, carcinogenesis in MASLD. Methods: A comprehensive literature was performed using PubMed identify relevant published studies. Eligible articles included original research clinical studies addressing immunological metabolic MASLD, well emerging therapeutic strategies. Results: We highlight cytokine networks, gut–liver axis, cell reprogramming. Emerging strategies, including inhibitors, anti-fibrotic agents, modulators, nutraceuticals, offer several indications for attenuating MASLD progression reducing prevalence extrahepatic manifestations. Conclusions: Given heterogeneity personalized combination-based approaches targeting both inflammation stress are essential effective management prevention complications.

Язык: Английский

Процитировано

0